An Experimental and Computational Protocol to Study Cell Proliferation in Human Acute Myeloid Leukemia Xenografts

Vlachou, Thalia; Nobile, Marco S.; Ronchini, Chiara; Besozzi, Daniela; Pelicci, Pier Giuseppe

doi:10.1007/978-1-0716-0810-4_14

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acute myeloid leukaemia (AML) is a common haematological malignancy with a high recurrence rate and mortality. 1 The growth of malignant cells is characterised by the interruption of normal intracellular signals caused by mutation or abnormal external signals. 2 There are few effective treatments for AML, partly due to the molecular heterogeneity of AML.…”

Section: Introductionmentioning

confidence: 99%

Prognostic significance ofKMT2A-PTD in patients with acute myeloid leukaemia: a systematic review and meta-analysis

et al. 2023

BMJ Open

View full text Add to dashboard Cite

ObjectivesWhetherKMT2A-PTD has a prognostic impact on patients with acute myeloid leukaemia (AML) is controversial. Therefore, we conducted a meta-analysis to assess the prognostic value ofKMT2A-PTD in patients with AML.MethodsEligibility criteria: we included studies concerning the prognostic value ofKMT2A-PTD in patients with AML.Information sources: Eligible studies were identified from PubMed, Embase, Medline, Web of Science, Cochrane Library and Chinese Biomedical Database. The systematic search date was 19 December 2020.Risk of bias: Sensitivity analysis was used to evaluate the stability and reliability of the combined results. Begg’s and Egger’s tests were used to assess the publication biases of studies.Synthesis of results: We calculated the pooled HRs and their 95% CIs for overall survival (OS) and event-free survival (EFS) by Stata V.12 software.ResultsIncluded studies: 18 studies covering 6499 patients were included.Synthesis of results:KMT2A-PTD conferred shorter OS in total population (HR=1.30, 95% CI 1.09 to 1.51). In the subgroup analysis,KMT2A-PTD also resulted in shorter OS in karyotypically normal AML patients (HR=2.72, 95% CI 1.83 to 3.61) and old AML patients (HR=1.93, 95% CI 1.44 to 2.42).KMT2A-PTD indicated no prognostic impact on EFS in total population (HR=1.26, 95% CI 0.86 to 1.66). However, in the sensitivity analysis,KMT2A-PTD resulted in poor EFS (HR=1.34, 95% CI 1.04 to 1.64) when deleting the study with a relatively obvious effect on the combined HR. In the subgroup analysis,KMT2A-PTD was associated with poor EFS in old AML patients (HR=1.64, 95% CI 1.25 to 2.03).ConclusionThe findings indicated thatKMT2A-PTD had an adverse impact on the prognosis of patients with AML in the total population, and the conclusion can also be applied to some subgroups including karyotypically normal AML and old AML patients.KMT2A-PTD may be a promising genetic biomarker in patients with AML in the future.Trial registration numberCRD42021227185.

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic significance ofKMT2A-PTD in patients with acute myeloid leukaemia: a systematic review and meta-analysis

et al. 2023

BMJ Open

View full text Add to dashboard Cite

show abstract

An Experimental and Computational Protocol to Study Cell Proliferation in Human Acute Myeloid Leukemia Xenografts

Cited by 1 publication

References 10 publications

Prognostic significance ofKMT2A-PTD in patients with acute myeloid leukaemia: a systematic review and meta-analysis

Prognostic significance ofKMT2A-PTD in patients with acute myeloid leukaemia: a systematic review and meta-analysis

Contact Info

Product

Resources

About